Online inquiry

IVTScrip™ mRNA-Anti-KDR, Angiocept(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2990MR)

This product GTTS-WQ2990MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets KDR gene. The antibody can be applied in Colorectal Cancer (CRC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_002253.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3791
UniProt ID P35968
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-KDR, Angiocept(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ2990MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1734MR IVTScrip™ mRNA-Anti-CD40, ADC-1013(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ADC-1013
GTTS-WQ2528MR IVTScrip™ mRNA-Anti-CALCRL, AMG 334(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG 334
GTTS-WQ4151MR IVTScrip™ mRNA-Anti-PDCD1, BI-754091(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BI-754091
GTTS-WQ13559MR IVTScrip™ mRNA-Anti-GPI-APs, PRX-302(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA PRX-302
GTTS-WQ227MR IVTScrip™ mRNA-Anti-B4GALNT1, 14.18 mAb(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 14.18 mAb
GTTS-WQ2200MR IVTScrip™ mRNA-Anti-IL15RA, ALT-803(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ALT-803
GTTS-WQ7041MR IVTScrip™ mRNA-Anti-EGFR, Fab C225(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Fab C225
GTTS-WQ14121MR IVTScrip™ mRNA-Anti-NGF, aNGF75(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA aNGF75
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW